{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000096","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.749923+00:00","generated_at":"2026-06-01T09:15:55.480023+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC","bullets":["Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.","OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.","ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.","Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000096","json":"https://secwatch.observer/filing/0001724521-24-000096.json","markdown":"https://secwatch.observer/filing/0001724521-24-000096.md","text":"https://secwatch.observer/filing/0001724521-24-000096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/0001724521-24-000096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000096/rcus-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T09:15:55.480023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}